Form 4 for APUS Apimeds Pharmaceuticals US, Inc.
Accepted 2025-05-20 00:00:00 ET · period of report 2025-05-16 · accession 0001474506-25-000100 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-20 | 2025-05-16 | APUS | Kim Christopher | COB, CMO, Dir | A - Grant | $0.00 | +250.0K | 277.5K | +909% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.01 per share | 2025-05-16 | A | A | 250,000 | $0.00 | 277,500 | D | — | — |